



Virus-Like Particle and Nano-Particle Vaccines 2.0

Guest Editors:

Prof. Dr. Kamil Kuca

Department of Chemistry,
Faculty of Science, University of
Hradec Králové, 50003 Hradec
Králové, Czech Republic

Prof. Dr. Jakub D. Rybka

Center for Advanced Technology,
Adam Mickiewicz University in
Poznań, Poland

Prof. Dr. Tomasz Pniewski

Institute of Plant Genetics, Polish
Academy of Sciences, 60-479
Poznań, Poland

Deadline for manuscript
submissions:

closed (28 February 2022)

Message from the Guest Editors

Nanotechnology is entering an increasing number of branches of science and common life. Nanoparticles of various types have been investigated for a wide variety of applications, including biomedicine. The special properties of virus-like particles have been used in vaccine development. Vaccination has saved many lives and vitally improved global health and life conditions. Nanobiotechnology could increase vaccine development. Nanoparticles, including virus-like particles, have extensive potential as vaccine vehicles, epitope carriers, adjuvants, and other nanobiomedical tools.

This Issue will be focused on nanobiotechnology applied in construction or modification of virus-like particles and vaccine development. Therefore, we welcome research articles, short communications, as well as review articles, of a high scientific level on the nanotechnological aspects of molecular virology, vaccinology, and immunology.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com